knowledge -WSS

knowledge

author：hotspot 2025-09-29 17:02:49 - browse：3

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： What's changing in Medicare's open enrollment this year?

WSS

How clinical AI models' predictive power can degrade over time

European regulators consider appeal over Amylyx ALS drug

Eight reasons why you should get an updated Covid vaccine

How doctors and nurses shape Google's AI

Readout LOUD podcast: Merger Mondays, Ozempic panic

Medicare to cover more brain scans related to Alzheimer’s drugs

hotspot

knowledge

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

What the Wegovy shortage looks like for doctors — and for patients

Wildfire smoke exposes gaps in outdoor worker protections

How should state employee insurance handle Wegovy?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Takeaways from AdvaMed, the largest medical devices conference

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare to cover more brain scans related to Alzheimer’s drugs

Hollywood unions extend contract negotiations for actors

Life sciences deals on track to hit lowest point since 2017

leisure time

Massive project maps cells in human brain in unprecedented detail

Akero's treatment for NASH falls short in cirrhosis study

Medicare to cover more brain scans related to Alzheimer’s drugs

What's changing in Medicare's open enrollment this year?

How should state employee insurance handle Wegovy?

Peter Marks talks Operation Warp Speed for Rare Diseases

leisure time

leisure time

focus

leisure time